Jump to content

TC-2216

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by WildCation (talk | contribs) at 16:49, 8 November 2016 (Drugbox edits: Added CSID, InChIs). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

TC-2216
Identifiers
  • 8-pyridin-3-yl-1,8-diazaspiro[4.4]nonane
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N3
Molar mass203.283 g·mol−1
3D model (JSmol)
  • N1CCCC1(CC2)CN2c3cnccc3
  • InChI=1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2
  • Key:NXIPMBQVNTWEEX-UHFFFAOYSA-N
  (verify)

TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and is being researched for the treatment of anxiety and depression.[1]

References

  1. ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.


Template:Nootropics